ULK1 Knockout HeLa Cell Line
Cat.No.:
EDJ-KQ20444
Species:
Human
Cell Name:
HeLa
Gene:
ULK1
Gene ID:
8408
Size:
1×10⁶cells
ULK1 Knockout Cell Line (Hela) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDJ-KQ20444 |
|---|---|
| Product Name | ULK1 Knockout Hela Cell Line |
| Cell Line | Hela |
| Cellosaurus ID | CVCL_0030 |
| Cell Line Synonyms | HELA, Hela, He La, He-La, HeLa-CCL2, Henrietta Lacks cells, Helacyton gartleri |
| Gene | ULK1 |
| NCBI Gene ID | |
| Gene Synonyms | ATG1|ATG1A|UNC51|Unc51.1|hATG1 |
| Summary |
Enables identical protein binding activity; protein serine/threonine kinase activity; and small GTPase binding activity. Involved in several processes, including autophagosome assembly; protein phosphorylation; and regulation of autophagy. Located in bounding membrane of organelle; cytosol; and phagophore assembly site membrane. Part of Atg1/ULK1 kinase complex. Is active in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]
|
| Associated Diseases | Cervical Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1/5, 2days |
| Complete Culture Medium | MEM + 10% FBS |
| Freezing Medium | 70%Complete culture medium+ 20% FBS+ 10% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HeLa | STR Info (Cell bank) Cell Line: HeLa | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1PO | 9 | 10 | 9 | 10 |
| D1S1656 | 12 | 15 | 12 | 15 |
| D2S1338 | 17 | 17 | ||
| D3S1358 | 15 | 18 | 15 | 18 |
| D5S818 | 11 | 12 | 11 | 12 |
| D6S1043 | 18 | 18 | ||
| D7S820 | 8 | 12 | 8 | 12 |
| D8S1179 | 12 | 13 | 12 | 13 |
| D12S391 | 20 | 25 | 20 | 25 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 10 | 9 | 10 |
| D18S51 | 16 | 16 | ||
| D19S433 | 13 | 14 | 13 | 14 |
| D21S11 | 27 | 28 | 27 | 28 |
| FGA | 18 | 21 | 18 | 21 |
| Penta D | 8 | 15 | 8 | 15 |
| Penta E | 7 | 17 | 7 | 17 |
| TPOX | 8 | 12 | 8 | 12 |
| VWA | 16 | 18 | 16 | 18 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Related Publications
Opposing roles for AMPK in regulating distinct mitophagy pathways.
IF=16.6
Molecular cell
TBC1D4 antagonizes RAB2A-mediated autophagic and endocytic pathways.
IF=14.3
Autophagy
Artificial targeting of autophagy components to mitochondria reveals both conventional and unconventional mitophagy pathways.
IF=14.3
Autophagy
EGCG-induced selective death of cancer cells through autophagy-dependent regulation of the p62-mediated antioxidant survival pathway.
IF=3.7
Biochimica et biophysica acta. Molecular cell research
Inhibition of Autophagy Alters Intracellular Transport of APP Resulting in Increased APP Processing.
IF=2.5
Traffic (Copenhagen, Denmark)
This KO model may be useful for:
- Investigating the role of ULK1 in distinct mitophagy pathways and AMPK signaling.
- Studying both conventional and unconventional autophagy pathways via mitochondrial targeting.
- Exploring crosstalk between autophagy and endocytic pathways mediated by RAB2A and TBC1D4.
- Evaluating autophagy-dependent cell survival mechanisms, such as p62-mediated antioxidant pathways in cancer cells.
- Analyzing autophagy’s impact on intracellular trafficking and processing of APP in neurodegenerative disease models.